

Amendments to the Claims

This listing of claims will replace all prior version and listings of claims in the application:

Listing of Claims:

1. (Currently amended): Combined pharmaceutical preparation for cancer therapy comprising as active [[substances]]substances:
 - a) at least one compound having glutaminase [[activity]]activity; and
 - b) at least one antineoplastic agent selected from platinum complexes and anthracyclines.
2. (Original): Preparation as claimed in claim 1, characterized in that the compound having glutaminase activity is a glutaminase, glutaminase-asparaginase, glutaminase analogue, derivative or modification of the same and is either of natural origin or is produced synthetically.
3. (Original): Preparation as claimed in claim 2, characterized in that the compound having glutaminase activity is from *Pseudomonas* and is preferably *Pseudomonas 7A* glutaminase-asparaginase.
4. (Currently amended): Preparation as claimed in claim 1one of the claims 1 to 3, characterized in that the compound having glutaminase activity is modified preferably with polyethylene glycol.

5. (Currently amended): Preparation as claimed in ~~claim 1 one of the claims 1 to 4~~, characterized in that it comprises doxorubicin, daunomycin, actinomycin D or/and mitoxantrone.
6. (Currently amended): Preparation as claimed in ~~claim 1 one of the claims 1 to 5~~, characterized in that it comprises cis-platinum, oxaliplatinum or/and carboplatinum.
7. (Currently amended): Process for producing pharmaceutical preparations as claimed in ~~claim 1 one of the claims 1 to 6~~, characterized in that the active substances optionally together with common pharmaceutical carrier substances or auxiliary substances are mixed and processed into oral or parenteral forms of administration.
8. (Original): Use of in particular a compound having glutaminase activity and at least one antineoplastic agent selected from platinum complexes and anthracyclines to produce an agent for an antineoplastic therapy.
9. (Withdrawn): Method for treating cancer and other diseases which are associated with abnormal cell proliferation, characterized in that at least one compound having glutaminase activity and at least one antineoplastic agent selected from platinum complexes or anthracyclines are administered in a molar ratio between 1:10 to 1:1000 and 10:1 to 1000:1, where the doses to be administered daily are 0.005 – 100 mg/kg body weight per individual component.